Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 801–900 of 1,004
Cuculi, F., Lim, C. C. S., & BANNING, A. P. (2010) · Heart · doi:10.1136/hrt.2009.186189 · Cited by 70
“The novel thienopyridine, prasugrel, and ticagrelor, a novel non-thienopyridine ADP receptor blocker, have shown promising results compared with clopidogrel in patients with ACS”
Antiplatelet drugs: which targets for which treatments?
Gachet, C. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12947 · Cited by 77
Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?
Sibbing, D., Kastrati, A., & Berger, P. B. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv717 · Cited by 76
“ACS patients in whom PCI was planned following the results of the TRITON-TIMI 34 trial.(8) In 13 608 ACS patients (including patients with unstable angina, NSTEMI, and STEMI), prasugrel reduced the risk of ischaemic events compared with clopidogrel when given immediately before the PCI procedure [9.”
MethodPalmerini, T., & Stone, G. W. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv712 · Cited by 70
“Some evidence suggests a possible association between cancer-related deaths and prolonged DAPT with either clopidogrel, prasugrel, or ticagrelor.(1,15,42) A simi-”
BackgroundEfficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization
Winchester, D. E., Wen, X., Brearley, W. D., Park, K. E., Anderson, R. D., & Bavry, A. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.030 · Cited by 66
Atherosclerosis: from biology to pharmacological treatment
Riccioni, G., & Sblendorio, V. T. (2012) · 老年心脏病学杂志:英文版 · doi:10.3724/sp.j.1263.2012.02132 · Cited by 82
D’Souza, M., Sarkisian, L., Saaby, L., Poulsen, T. S., Gerke, O., Larsen, T. B., Diederichsen, A. C. P., Jangaard, N., Diederichsen, S. Z., Hosbond, S. E., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.044 · Cited by 70
Gagne, J. J., Bykov, K., Choudhry, N. K., Toomey, T., Connolly, J. G., & Avorn, J. (2013) · BMJ · doi:10.1136/bmj.f5307 · Cited by 67
Alexopoulos, D., Moulias, A., Koutsogiannis, N., Xanthopoulou, I., Kakkavas, A., Mavronasiou, E., Davlouros, P., & Hahalis, G. (2013) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.113.000293 · Cited by 66
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Velders, M. A., Abtan, J., Angiolillo, D. J., Ardissino, D., Harrington, R. A., Hellkamp, A. S., Himmelmänn, A., Husted, S., Katus, H. A., Meier, B., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308963 · Cited by 70
Self-citationAntiplatelet therapy – a summary for the general physicians
Thachil, J. V. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-2-152 · Cited by 83
Role of genetic testing in patients undergoing percutaneous coronary intervention
Moon, J. Y., Franchi, F., Rollini, F., Rios, J. R. R., Kureti, M., Cavallari, L. H., & Angiolillo, D. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1353909 · Cited by 69
“(ICH) and overall net harm, reason for which prasugrel is contraindicated in these patients [25].”
Olier, I., Sirker, A., Hildick‐Smith, D., Kinnaird, T. D., Ludman, P., de Belder, M., Baumbach, A., Byrne, J., Rashid, M. O., Curzen, N. P., et al. (2018) · Heart · doi:10.1136/heartjnl-2017-312366 · Cited by 66
Kwok, C. S., Rao, S. V., Potts, J. E., Kontopantelis, E., Rashid, M. O., Kinnaird, T. D., Curzen, N. P., Nolan, J., Bagur, R., & Mamas, M. A. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.01.248 · Cited by 67
“struts, which reduce stent thrombosis (23,24) and powerful antiplatelet agents, which reduce major adverse cardiovascular events (25,26) and stent thrombosis (26,27).”
BackgroundBosch, X., Marrugat, J., & Sanchis, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002130.pub4 · Cited by 69
Cardiovascular Disease in Women
Stock, E. O., & Redberg, R. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.001 · Cited by 65
Hsu, S., Ton, V., Ashen, M. D., Martin, S. S., Gluckman, T. J., Kohli, P., Sisson, S. D., Blumenthal, R. S., & Blaha, M. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22137 · Cited by 69
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 75
De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes
Shoji, S., Kuno, T., Fujisaki, T., Takagi, H., Briasoulis, Α., Deharo, P., Cuisset, T., Latib, A., & Kohsaka, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.012 · Cited by 68
Kwon, O., & Park, D. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.12.005 · Cited by 71
“Along with the key findings in the large-scaled PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial that a 60-mg dose of ticagrelor might offer a more attractive risk-ben…”
BackgroundInfluentialAntithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Valgimigli, M., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Halvorsen, S., James, S. K., Jüni, P., Kunadian, V., Landi, A., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad032 · Cited by 67
Self-citationDiagnosis and Management of Ischemic Heart Disease
Franchini, M., Cervellin, G., & Lippi, G. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333543 · Cited by 70
Parodi, G., Bellandi, B., Venditti, F., Carrabba, N., Valenti, R., Migliorini, A., Grassellini, S., Ramazzotti, E., & Antoniucci, D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.034 · Cited by 64
Prevention of stent thrombosis: challenges and solutions
Lotfi, A. S., & Reejhsinghani, R. S. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s43357 · Cited by 71
Sánchez-Ramos, J. G., Dávila-Fajardo, C. L., Frías, P. T., Díaz-Villamarín, X., Martínez-González, L. J., Huertas, S. M., Gómez, F. B., Borrego, J. C., Pavés, A. B., Guzmán, M. C. M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.088 · Cited by 65
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“99,100 In ACS treated with percutaneous coronary intervention (PCI), ticagrelor is also superior to clopidogrel.”
Lee, S., Park, S., Yun, S., Kim, Y., Park, D., Kim, W., Lee, J., Lee, C. W., Hong, M., Kim, J., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2009.11.014 · Cited by 66
Würtz, M., & Grove, E. L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803251925 · Cited by 71
Yun, J. E., Kim, Y. J., Park, J. J., Kim, S., Park, K., Cho, M. S., Nam, G., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012078 · Cited by 71
“The key findings of our study conflicted with those of the pivotal RCTs of ticagrelor and prasugrel.(2,3) In our study, compared with clopidogrel, ticagrelor use significantly increased the rate of bleeding events without reducing major cardiovascular events.”
ResultKutcher, S., Brophy, J. M., Banack, H. R., Kaufman, J. S., & Samuel, M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.05.012 · Cited by 87
Flechtenmacher, N., Kämmerer, F., Dittmer, R., Budde, U., Michels, P., Röther, J., & Eckert, B. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4388 · Cited by 64
Luca, G. D., Navarese, E. P., Cassetti, E., Verdoia, M., & Suryapranata, H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.063 · Cited by 64
Management of Anticoagulation Before and After Gastrointestinal Endoscopy
Kwok, A., & Faigel, D. O. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.469 · Cited by 67
“Prasugrel is a new thienopyridine that has been assessed recently in a Phase III clinical trial, trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction (TRITON-TIMI) 38 (”
BackgroundWiviott, S. D., Desai, N. R., Murphy, S. A., Musumeci, G., Ragosta, M., Antman, E. M., & Braunwald, E. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.05.020 · Cited by 62
Self-citationClinical evidence for oral antiplatelet therapy in acute coronary syndromes
Wiviott, S. D., & Steg, P. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60213-6 · Cited by 76
Self-citationNishiya, Y., Hagihara, K., Kurihara, A., Okudaira, N., Farid, N. A., Okazaki, O., & Ikeda, T. (2009) · Xenobiotica · doi:10.3109/00498250903191427 · Cited by 64
“Furthermore, prasugrel showed superior efficacy to clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention (Wiviott et al. 2007).”
BackgroundLarmore, C. J., Effron, M. B., Molife, C., DeKoven, M., Zhu, Y. E., Lu, J., Karkare, S. U., Lieu, H. D., Lee, W. C., & Vetrovec, G. W. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26279 · Cited by 69
Gremmel, T., Yanachkov, I. B., Yanachkova, M. I., Wright, G. E., Wider, J. M., Undyala, V. V. R., Michelson, A. D., Frelinger, A. L., & Przyklenk, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306885 · Cited by 67
Park, T. K., Song, Y. B., Ahn, J., Carriere, K. C., Hahn, J., Yang, J. H., Choi, S., Choi, J., Lee, S. H., & Gwon, H. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.002816 · Cited by 65
Management of acute coronary syndromes in older adults
Morici, N., Servi, S. D., Luca, L. D., Crimi, G., Montalto, C., Rosa, R. D., Luca, G. D., Rubboli, A., Valgimigli, M., & Savonitto, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab391 · Cited by 69
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Ma, T. K. W., Lam, Y., Tan, V. P. Y., & Yan, B. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03949.x · Cited by 63
Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature
Rogers, K. C., Oliphant, C. S., & Finks, S. W. (2015) · Drugs · doi:10.1007/s40265-015-0364-3 · Cited by 70
Xie, H., Zou, J., Hu, Z., Zhang, J., Ye, F., & Chen, S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.001 · Cited by 73
Aspirin Resistance: Current Status and Role of Tailored Therapy
Grinstein, J., & Cannon, C. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22031 · Cited by 70
Kubica, A., Obońska, K., Fabiszak, T., & Kubica, J. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1182901 · Cited by 69
Ticagrelor – toward more efficient platelet inhibition and beyond
Kubisa, M. J., Jeżewski, M. P., Gąsecka, A., Siller-Matula, J. M., & Postula, M. A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s152369 · Cited by 72
“potent P2Y12 receptor antagonist, ticagrelor, and prasugrel reduced the rate of ischemic events compared to clopidogrel.(5,6) Subsequently, ticagrelor and prasugrel have been Correspondence: Marek Postuła Department of experimental and Clinical Pharmacology, Center for Preclinical Research and Technology (CePT), Medic…”
Kang, J., Han, J., Ahn, Y., Chae, S. C., Kim, Y. J., Chae, I., Hur, S., Seong, I. W., Chae, J.-K., Cho, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1626697 · Cited by 65
Werdan, K., & Ruß, M. (2011) · Intensivmedizin und Notfallmedizin · doi:10.1007/s00390-011-0313-7 · Cited by 62
Laine, M., Frère, C., Toesca, R., Berbis, J., Barnay, P., Pansiéri, M., Michelet, P., Bessereau, J., Camilleri, É., Ronsin, O., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0384 · Cited by 68
Clopidogrel withdrawal: Is there a “rebound” phenomenon?
Sambu, N., Warner, T. D., & Curzen, N. P. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0554 · Cited by 68
Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.
Levi, M. M., Eerenberg, E. S., Löwenberg, E. C., & Kamphuisen, P. W. (2010) · PubMed · Cited by 62
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity
Chau, K. H.-Y., Kirtane, A. J., Easterwood, R. M., Redfors, B., Zhang, Z., Witzenbichler, B., Weisz, G., Stuckey, T., Brodie, B. R., Rinaldi, M. J., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.12.005 · Cited by 65
Self-citationPoor response to clopidogrel: current and future options for its management
Campo, G. C., Fileti, L., Valgimigli, M., Tebaldi, M., Cangiano, E., Cavazza, C., Marchesini, J., & Ferrari, R. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0457-5 · Cited by 62
“The relative rate of TIMI (thrombolysis in myocardial infarction) major haemorrhage was increased by 32% with prasugrel [38].”
BackgroundMethodInfluentialLemesle, G., Schurtz, G., Bauters, C., & Hamon, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12907 · Cited by 61
Nishiya, Y., Hagihara, K., Ito, T., Tajima, M., Miura, S., Kurihara, A., Farid, N. A., & Ikeda, T. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022988 · Cited by 62
“, 2007) and efficacy superior to that of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention (Wiviott et al., 2007).”
BackgroundAbtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Ikeda, Y., Wu, D., Hanson, M. E., Hannachi, H., Singhal, P. K., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22583 · Cited by 66
Généreux, P., Giustino, G., Redfors, B., Palmerini, T., Witzenbichler, B., Weisz, G., Stuckey, T., Maehara, A., Mehran, R., Kirtane, A. J., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.103 · Cited by 65
Platelets in Host Defense: Experimental and Clinical Insights
Nicolai, L., Gaertner, F. C., & Maßberg, S. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.004 · Cited by 70
Acute, periprocedural and longterm antithrombotic therapy in older adults
Andreotti, F., Geisler, T., Collet, J., Gigante, B., Gorog, D. A., Halvorsen, S., Lip, G. Y. H., Morais, J., Navarese, E. P., Patrono, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac515 · Cited by 70
Making Sense of Composite Endpoints in Clinical Research
Baracaldo-Santamaría, D., Feliciano-Alfonso, J. E., Grueso, R. R., Rojas-Rodríguez, L. C., Domínguez-Domínguez, C. A., & Calderón‐Ospina, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134371 · Cited by 74
“TRITON-TIMI-38 MACE: death from cardiovascular causes, nonfatal MI, or nonfatal stroke Treatment with prasugrel compared with clopidogrel reduced the rate of the composite endpoint -Current guidelines for the treatment of NSTEMI and STEMI recommend the use of prasugrel over clopidogrel [9,10,21]”
MethodSmall, D. S., Farid, N. A., Payne, C. D., Konkoy, C. S., Jakubowski, J. A., Winters, K. J., & Salazar, D. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11537820-000000000-00000 · Cited by 60
Teng, R. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630960-000000000-00000 · Cited by 62
“Prasugrel, another thienopyridine, has demonstrated more potent and consistent inhibition of platelet aggregation (IPA) than clopidogrel.([11]) However, prasugrel also requires metabolic activation and treatment is associated with a significantly increased risk of life-threatening and fatal bleeding compared with clop…”
BackgroundKikkert, W. J., Claessen, B. E. P. M., Stone, G. W., Mehran, R., Witzenbichler, B., Brodie, B. R., Wöhrle, J., Witkowski, A., Guagliumi, G., Zmudka, K. F., et al. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0953-5 · Cited by 60
“Although antithrombotic therapy reduces this risk, it increases the risk for hemorrhagic complications [2, 3].”
BackgroundTicagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome
Törngren, K., Öhman, J. N., Salmi, H., Larsson, J., & Erlinge, D. (2013) · Cardiology · doi:10.1159/000347122 · Cited by 62
Valle, J. A., Shetterly, S. M., Maddox, T. M., Ho, P. M., Bradley, S. M., Sandhu, A., Magid, D. J., & Tsai, T. T. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.003519 · Cited by 65
The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence
Leader, A., Zelikson-Saporta, R., Pereg, D., Spectre, G., Rozovski, U., Raanani, P., Hermoni, D., & Lishner, M. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.022 · Cited by 71
Arntz, H.-R., Bossaert, L. L., Danchin, N., & Nikolaou, N. I. (2010) · Resuscitation · doi:10.1016/j.resuscitation.2010.08.016 · Cited by 75
“5 years [39].”
Faxon, D., Airaksinen, J., Schlitt, A., Marìn, F., Bhatt, D., Lip, G., & Rubboli, A. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-08-0681 · Cited by 60
Elinogrel: Pharmacological Principles, Preclinical and Early Phase Clinical Testing
Ueno, M., Rao, S. V., & Angiolillo, D. J. (2010) · Future Cardiology · doi:10.2217/fca.10.67 · Cited by 60
“A large clinical trial demonstrated prasugrel to be superior to standard-dose clopidogrel in reducing ischemic events in patients with ACS undergoing PCI, although prasugrel was asso ciated with a significantly higher risk of major bleeding events [20].”
BackgroundBraun, O. Ö., Bico, B., Chaudhry, U. A., Wagner, H., Koul, S. M., Tydén, P., Scherstén, F., Jovinge, S. V., Svensson, P. J., Smith, J. G., et al. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.016 · Cited by 61
“5% for ticagrelor [21,22].”
Precision Cardiovascular Medicine: State of Genetic Testing
Giudicessi, J. R., Kullo, I. J., & Ackerman, M. J. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.015 · Cited by 65
Ogawa, A., Toyoda, Ḱ., Kitagawa, K., Kitazono, T., Nagao, T., Yamagami, H., Uchiyama, S., Tanahashi, N., Matsumoto, M., Minematsu, K., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30449-6 · Cited by 61
Joshi, A., Schmidt, L. E., Burnap, S. A., Lu, R., Chan, M. V., Armstrong, P. C. J., Baig, F., Gutmann, C., Willeit, P., Santer, P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317113 · Cited by 60
Zafar, M. U., Santos‐Gallego, C. G., Vorchheimer, D. A., Viles-González, J. F., Elmariah, S., Giannarelli, C., Sartori, S., Small, D. S., Jakubowski, J. A., Fuster, V., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12058 · Cited by 60
Musumeci, G., Capodanno, D., Lettieri, C., Limbruno, U., Tarantini, G., Russo, N., Calabria, P., Romano, M., Inashvili, A., Sirbu, V., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0436 · Cited by 60
Clopidogrel and Proton Pump Inhibitors
Tantry, U. S., Kereiakes, D. J., & Gurbel, P. A. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.009 · Cited by 60
Hochholzer, W., Trenk, D., Mega, J. L., Morath, T., Stratz, C., Valina, C. M., O’Donoghue, M. L., Bernlochner, I., Contant, C. F., Guo, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.005 · Cited by 64
Self-citationCalabrò, P., Gragnano, F., Maio, M. D., Patti, G., Antonucci, E., Cirillo, P. L., Gresele, P., Palareti, G., Pengo, V., Pignatelli, P., et al. (2018) · Angiology · doi:10.1177/0003319718760917 · Cited by 61
Gandhi, S., Garratt, K. N., Li, S., Wang, T. Y., Bhatt, D. L., Davis, L. L., Zeitouni, M., & Kontos, M. C. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008112 · Cited by 63
Brieger, D. B., Cullen, L., Briffa, T. G., Zaman, S. J., Scott, I. A., Papendick, C., Bardsley, K., Baumann, A. A. W., Bennett, A., Clark, R. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.02.102 · Cited by 74
Mangiacapra, F., Müller, O., Ntalianis, A., Trana, C., Heyndrickx, G. R., Bartúnek, J., Vanderheyden, M., Wijns, W. C., Bruyne, B. D., & Barbato, E. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.044 · Cited by 59
Serebruany, V. L., Rao, S. V., Silva, M. A., Donovan, J. L., Kannan, A. O., Makarov, L., Goto, S., & Atar, D. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp434 · Cited by 59
Rollini, F., Franchi, F., Cho, J. R., DeGroat, C., Bhatti, M., Muñiz‐Lozano, A., Singh, K., Ferrante, E., Wilson, R. E., Dunn, E. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv744 · Cited by 63
Melloni, C., Cornel, J. H., Hafley, G. E., Neely, M. L., Clemmensen, P. M., Zamoryakhin, D., Prabhakaran, D., White, H. D., Fox, K. A. A., Ohman, E. M., et al. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615598631 · Cited by 63
Reperfusion strategies in acute myocardial infarction and multivessel disease
Vogel, B., Mehta, S. R., & Mehran, R. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.88 · Cited by 60
Gargiulo, G., Valgimigli, M., Capodanno, D., & Bittl, J. A. (2017) · EuroIntervention · doi:10.4244/eij-d-17-00468 · Cited by 63
Huber, C. A., Meyer, M. R., Steffel, J., Blozik, E., Reich, O., & Rosemann, T. J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.012 · Cited by 73
Antithrombotics in Acute Coronary Syndromes
Bonaca, M. P., Steg, P. G., Feldman, L. J., Canales, J. F., Ferguson, J. J., Wallentin, L. C., Califf, R. M., Harrington, R. A., & Giugliano, R. P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.083 · Cited by 66
Abraham, N. S., Noseworthy, P. A., Inselman, J., Herrin, J. S., Yao, X., Sangaralingham, L. R., Cornish, G., Ngufor, C. G., & Shah, N. D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.017 · Cited by 69
Revisiting secondary prevention in coronary heart disease
Sigamani, A., & Gupta, R. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.011 · Cited by 87
Ndounga Diakou, L. A., Trinquart, L., Hróbjartsson, A., Barnes, C., Yavchitz, A., Ravaud, P., & Boutron, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000043.pub2 · Cited by 58
Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy
Yasuda, H., Matsuo, Y., Sato, Y., Ozawa, S.-I., Ishigooka, S., Yamashita, M., Yamamoto, H., & Itoh, F. (2015) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v4.i1.40 · Cited by 70
Nakamura, M., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Ikeda, Y., & Saito, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.026 · Cited by 59
“It is also notable that the HR for the incidence of MACEwas similar to that in each region of TRITON-TIMI 38 [11].”
BackgroundResultCheema, A. N., Mohammad, A., Hong, T., Jakubovic, H. R., Parmar, G., Sharieff, W., Garvey, M. B., Kutryk, M. J. B., Fam, N., Graham, J. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.040 · Cited by 58
Hansi, C., Arab, A., Rzany, A., Ahrens, I., Bode, C., & Hehrlein, C. (2009) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21834 · Cited by 58
“such as the substance prasugrel may present an alternative because of the increasing bleeding complications [27].”
BackgroundGruber, S. C., Grove, E. L., Weiss, T. W., Wojta, J., Huber, K., & Freynhofer, M. K. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0179 · Cited by 62
“In light of the successful arrival of more potent P2Y12-receptor blocking agents, prasugrel and ticagrelor, in the ACS arena the neutral studies with regard to tailored antiplatelet therapy seem to have limited impact (13, 14, 102, 103).”
BackgroundChiarito, M., Cao, D., Cannata, F., Godino, C., Lodigiani, C., Ferrante, G., Lópes, R. D., Alexander, J. H., Reimers, B., Condorelli, G., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5306 · Cited by 64
Novel aspects of antiplatelet therapy in cardiovascular disease
Gremmel, T., Michelson, A. D., Frelinger, A. L., & Bhatt, D. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12115 · Cited by 61
van Leeuwen, M. A. H., van der Hoeven, N. W., Janssens, G. N., Everaars, H., Nap, A., Lemkes, J. S., de Waard, G. A., van de Ven, P. M., van Rossum, A. C., ten Cate, T. J. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035931 · Cited by 61
Clemmensen, P. M., Grieco, N. B., İnce, H., Danchin, N., Gödicke, J., Ramos, Y., Schmitt, J., Goldstein, P., & on behalf of the MULTIPRAC study investigators (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614547449 · Cited by 58
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.